Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases
Launched by BIOGENESI · Sep 17, 2012
Trial Information
Current as of May 29, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - At least one (maximum 3) miscarriage and/or biochemical pregnancy after ART treatment
- Exclusion Criteria:
- • Frozen spermatozoa
- • Frozen oocytes
- • women with PCO and PCOS
- • women with more than 4 ART treatments
About Biogenesi
Biogenesi is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs. With a strong emphasis on research and development, Biogenesi focuses on the discovery and commercialization of novel treatments for various complex diseases. The company is committed to enhancing patient outcomes through rigorous clinical trials and collaborations with healthcare professionals, ensuring that its products are not only effective but also safe and accessible. Biogenesi's mission is to transform healthcare through science and innovation, ultimately improving the quality of life for patients around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monza, Mb, Italy
Patients applied
Trial Officials
Mariabeatrice Dal Canto, PhD
Principal Investigator
Biogenesi Reproductive medicine Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials